Blood test-guided treatment for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with non-small cell lung cancer (a common type of lung cancer).
- Your lung cancer is stage IIIB or IIIC (meaning it has spread within the chest but not to distant organs) and may be removable by surgery.
- You have not had any prior treatment (chemotherapy, radiation, or immunotherapy) for your lung cancer.
- You do not have specific gene changes (like EGFR or ALK) in your cancer.
- You are generally physically active (able to do light activities) and willing to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study is for people with advanced non-small cell lung cancer whose tumors do not have certain genetic changes (called driver mutations) and whose first treatment did not work well or caused bad side effects within 6 months. The researchers want to use a special test (DNA/RNA-NGS) to look for hidden genetic alterations that might explain why the cancer didn't respond.
This study looks at a new blood test to predict how well standard-of-care chemotherapy plus immunotherapy works for people with advanced non-small cell lung cancer. It aims to personalize treatment by identifying patients who may benefit most, potentially improving outcomes and reducing unnecessary side effects.
This trial studies if a blood test that looks for tumor DNA combined with a PET-CT scan can better predict if lung cancer has spread to lymph nodes. It may help guide treatment decisions for people with non-small cell lung cancer that hasn't been treated yet.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.